You are here:

Archived: nebivolol tablets 5mg (Nebilet)


Following a full submission.

Nebivolol (Nebilet®) is not recommended for use within NHS Scotland for the treatment of stable mild and moderate chronic heart failure (CHF) in addition to standard therapies in elderly patients ≥70 years. Nebivolol, added to standard therapy, was associated with improved left ventricular function and a reduction in a composite endpoint combining all cause mortality and cardiovascular hospitalisation rates in elderly patients with chronic heart failure.There is no comparison with other beta-adrenoceptor blockers.

Cost effectiveness relative to other beta-adrenoceptor blockers in common use in chronic heart failure has not been demonstrated.

Drug Details

Drug Name: nebivolol tablets 5mg (Nebilet)
SMC Drug ID: 214/05
Manufacturer: Menarini Pharmaceuticals UK
Indication: Stable mild and moderate chronic heart failure
BNF Category:
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 11 September 2006

Current Advice

Resubmission 13 August 2007